A trial currently recruiting patients is testing a new way to deliver the active metabolite of Irinotecan to tumors:
http://www.tarveda.com/PEN-866.html
Irinotecan is often used in pediatric sarcoma but it’s unclear from the medical literature whether it can be effective in synovial sarcoma.